This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Neil C. Feinstein, MD; Benjamin Rubin, MD
Brooklyn, NY

Arch Ophthalmol. 1988;106(3):311.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Flurbiprofen sodium (0.03%) (Ocufen) is a recently approved nonsteroidal anti-inflammatory drug for the maintenance of intraoperative pupillary dilation during cataract surgery. Initial reports of its efficacy have been favorable.^1,2 There have been few reports of side effects. The package insert states that the most frequent reactions are transient burning and stinging on instillation. The insert also states that there is a hypothetical possibility of intraoperative hemorrhage via interference with thrombocyte aggregation. I recently encountered a perioperative complication that may be attributed to interference with the clotting mechanism.

Report of a Case.

—An 84-year-old man was scheduled to undergo extracapsular cataract extraction in the left eye with posterior chamber lens implantation. Before surgery, the patient was taking chlorpropamide and dipyridamole. One hour and 30 minutes before surgery, one drop of 0.03% flurbiprofen sodium was instilled into the left eye. In addition, 1% tropicamide and 2.25% phenylephrine . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?